Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Non-Current Liabilities (2019 - 2025)

China SXT Pharmaceuticals (SXTC) has 6 years of Total Non-Current Liabilities data on record, last reported at $211683.0 in Q1 2025.

  • For Q1 2025, Total Non-Current Liabilities fell 28.16% year-over-year to $211683.0; the TTM value through Mar 2025 reached $211683.0, down 28.16%, while the annual FY2025 figure was $211683.0, 28.16% down from the prior year.
  • Total Non-Current Liabilities reached $211683.0 in Q1 2025 per SXTC's latest filing, down from $294667.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $365823.0 in Q1 2023 and bottomed at $6292.0 in Q1 2021.
  • Average Total Non-Current Liabilities over 4 years is $219616.2, with a median of $253175.0 recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: plummeted 82.77% in 2021, then fell 19.45% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $6292.0 in 2021, then skyrocketed by 5714.1% to $365823.0 in 2023, then dropped by 19.45% to $294667.0 in 2024, then decreased by 28.16% to $211683.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $211683.0 in Q1 2025, $294667.0 in Q1 2024, and $365823.0 in Q1 2023.